Health Ministry-approved labeling says antiviral is effective within 2 minutes; can save many lives in countries without access to vaccines, says inventor
A nasal spray that will be marketed as capable of killing 99.9 percent of virus particles has started rolling off production lines in an Israeli factory.
The spray could have prevented much of the world’s COVID-19 infection, its inventor, Dr. Gilly Regev, told The Times of Israel.
********************************************************
SaNOtize has been evaluating nitric oxide (NO), a naturally occurring nanomolecule in the body, as a first-in-class nitrosylite drug with potential use as a topical antimicrobial agent to treat a wide variety of diseases.
SaNOtize has an issued patent for its Nitric Oxide Releasing Solution (NORSTM).
The company’s key objective is to provide a first-line non-antibiotic antimicrobial for use against bacterium, viruses and fungi. With this approach, antibiotic therapies may be reserved for more severe infections, used less frequently, and ultimately slow the development of AMR.
In addition to its ability to treat a broad spectrum of infectious pathogens, NORSTM delivery is practical and convenient. The development of a proprietary liquid formulation to generate NO as an antimicrobial and immunomodulatory agent means that high-pressure cylinders of gNO are not required for delivery.
********************************************************
Israel and New Zealand Permit Sale of SaNOtize’s Breakthrough Anti-Viral Nasal Spray
VANCOUVER, British Columbia & TEL AVIV, Israel–(BUSINESS WIRE)–
Biotech company SaNOtize Research & Development Corp., (SaNOtize) today announced that it has received interim approval to sell its Nitric Oxide Nasal Spray (NONS), which protects users from viruses that enter the body through the upper nasal pathways, to the public in pharmacies in Israel, and has been registered to begin sales of NONS in New Zealand.
“Our novel formulation of Nitric Oxide for use in humans is designed to kill viruses in the upper airways, preventing them from incubating and spreading to the lungs. The pharmacology, toxicity, and safety data for use in humans has been well-established for decades”
Manufacturing of NONS, under the brand name Enovid™, has begun in Israel with SaNOtize’s manufacturing partner Ness Ziona-based Nextar Chempharma Solutions Ltd. Enovid is expected to appear on pharmacy shelves in Israel by the summer.
In New Zealand, SaNOtize has registered its nasal spray with the New Zealand Medicines and Medical Devices Safety Authority, which permits the company to distribute and sell NONS over the counter immediately.
“The product we have developed, which kills viruses in the upper nasal pathways, will be delivered via a nasal spray bottle that contains a month’s supply for an individual,” said Dr. Gilly Regev, the Israeli CEO and co-founder of SaNOtize. “We look forward to updating the public in Israel and New Zealand with details on when Enovid will hit store shelves.”
Last week, SaNOtize and Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK announced results of clinical trials indicating that NONS represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. The study has been submitted to a leading medical journal for review and publication. You can read the news release here.
“Our novel formulation of Nitric Oxide for use in humans is designed to kill viruses in the upper airways, preventing them from incubating and spreading to the lungs. The pharmacology, toxicity, and safety data for use in humans has been well-established for decades,” said Dr. Chris Miller, Chief Science Officer and co-founder of SaNOtize. “Our innovative product design also allows the treatment to be self-administered effectively and affordably.”
